Seroprevalence of SARS-CoV-2 immunoglobulin G in HIV-positive and HIV-negative individuals in KwaZulu-Natal, South Africa

Background KwaZulu-Natal ranked second highest among South African provinces for the number of laboratory-confirmed cases during the second wave of the severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) pandemic. The seroprevalence of SARS-CoV-2 among certain vulnerable groups, such as people living with HIV in KwaZulu-Natal, is unknown. Objective The study aimed to determine the prevalence of SARS-CoV-2 immunoglobulin G (IgG) in HIV-positive versus HIV-negative patients. Methods This was a retrospective analysis of residual clinical blood specimens unrelated to coronavirus disease 2019 (COVID-19) submitted for diagnostic testing at Inkosi Albert Luthuli Central Hospital, Durban, from 10 November 2020 to 09 February 2021. Specimens were tested for SARS-CoV-2 immunoglobulin G on the Abbott Architect analyser. Results A total of 1977/8829 (22.4%) specimens were positive for SARS-CoV-2 antibodies. Seroprevalence varied between health districts from 16.4% to 37.3%, and was 19% in HIV-positive and 35.3% in HIV-negative specimens. Seroprevalence was higher among female patients (23.6% vs 19.8%; p < 0.0001) and increased with increasing age, with a statistically significant difference between the farthest age groups (< 10 years and > 79 years; p < 0.0001). The seroprevalence increased from 17% on 10 November 2020 to 43% on 09 February 2021 during the second wave. Conclusion Our results highlight that during the second COVID-19 wave in KwaZulu-Natal a large proportion of people living with HIV were still immunologically susceptible. The reduced seropositivity in people with virological failure further emphasises the importance of targeted vaccination and vaccine response monitoring in these individuals. What the study adds This study contributes to data on SARS-CoV-2 seroprevalence before and during the second wave in KwaZulu-Natal, South Africa, which has the highest HIV prevalence globally. Reduced seropositivity was found among people living with HIV with virological failure, highlighting the importance of targeted booster vaccination and vaccine response monitoring.

[1]  T. de Oliveira,et al.  Identification of SARS‐CoV‐2 Omicron variant using spike gene target failure and genotyping assays, Gauteng, South Africa, 2021 , 2022, Journal of medical virology.

[2]  Xinling Xu,et al.  High seroconversion rate after vaccination with mRNA BNT162b2 vaccine against SARS-CoV-2 among people with HIV - but HIV viremia matters? , 2022, AIDS.

[3]  J. Blackburn,et al.  Performance of the Abbott SARS-CoV-2 IgG serological assay in South African 2 patients , 2022, PloS one.

[4]  C. Alloui,et al.  Impaired antibody response to COVID-19 vaccination in advanced HIV infection , 2022, AIDS.

[5]  S. A. Abdool Karim,et al.  Impact of SARS-CoV-2 variants of concern on Covid-19 epidemic in South Africa , 2021, Transactions of the Royal Society of South Africa.

[6]  N. Cassim,et al.  Sentinel seroprevalence of SARS-CoV-2 in Gauteng Province, South Africa, August - October 2020. , 2021, South African medical journal = Suid-Afrikaanse tydskrif vir geneeskunde.

[7]  S. Madhi,et al.  Estimated SARS-CoV-2 infection rate and fatality risk in Gauteng Province, South Africa: a population-based seroepidemiological survey , 2021, International journal of epidemiology.

[8]  S. Tollman,et al.  SARS-CoV-2 Seroprevalence in a Rural and Urban Household Cohort during First and Second Waves of Infections, South Africa, July 2020–March 2021 , 2021, Emerging infectious diseases.

[9]  Christine S. Smedley,et al.  Difference in mortality among individuals admitted to hospital with COVID-19 during the first and second waves in South Africa: a cohort study , 2021, The Lancet Global Health.

[10]  S. Madhi,et al.  Asymptomatic COVID-19 in South Africa - implications for the control of transmission. , 2021, Public health action.

[11]  S. Letovsky,et al.  A population-based analysis of the longevity of SARS-CoV-2 antibody seropositivity in the United States , 2021, EClinicalMedicine.

[12]  M. Peluso,et al.  SARS-CoV-2 seroprevalence, and IgG concentration and pseudovirus neutralising antibody titres after infection, compared by HIV status: a matched case-control observational study , 2021, The Lancet HIV.

[13]  N. Cassim,et al.  Sentinel seroprevalence of SARS-CoV-2 in the Gauteng province, South Africa August to October 2020. , 2021, medRxiv.

[14]  Á. Soriano,et al.  Overview of SARS-CoV-2 infection in adults living with HIV , 2021, The Lancet HIV.

[15]  Sergei L. Kosakovsky Pond,et al.  Detection of a SARS-CoV-2 variant of concern in South Africa , 2021, Nature.

[16]  A. Welte,et al.  Prevalence of anti-SARS-CoV-2 antibodies among blood donors in Northern Cape, KwaZulu-Natal, Eastern Cape, and Free State provinces of South Africa in January 2021. , 2021, Research square.

[17]  S. Lee,et al.  Antibody Responses 8 Months after Asymptomatic or Mild SARS-CoV-2 Infection , 2020, Emerging infectious diseases.

[18]  M. Gandhi,et al.  The interplay between HIV and COVID-19: summary of the data and responses to date , 2020, Current opinion in HIV and AIDS.

[19]  G. Pantaleo,et al.  Changes in SARS-CoV-2 Spike versus Nucleoprotein Antibody Responses Impact the Estimates of Infections in Population-Based Seroprevalence Studies , 2020, Journal of Virology.

[20]  M. Leeflang,et al.  SARS-CoV-2 seroprevalence worldwide: a systematic review and meta-analysis , 2020, Clinical Microbiology and Infection.

[21]  A. Giacomelli,et al.  Seroprevalence of SARS-CoV-2 significantly varies with age: Preliminary results from a mass population screening , 2020, Journal of Infection.

[22]  C. Viboud,et al.  Serological evidence of human infection with SARS-CoV-2: a systematic review and meta-analysis , 2020, The Lancet Global Health.

[23]  D. Gill,et al.  Are we underestimating seroprevalence of SARS-CoV-2? , 2020, BMJ.

[24]  G. Alter,et al.  The Power of Antibody-Based Surveillance , 2020, The New England journal of medicine.

[25]  H. Rees,et al.  The role of serological testing in the SARS-CoV-2 outbreak. , 2020, South African medical journal = Suid-Afrikaanse tydskrif vir geneeskunde.

[26]  P. Glasziou,et al.  Comparison of seroprevalence of SARS-CoV-2 infections with cumulative and imputed COVID-19 cases: Systematic review , 2020, PloS one.

[27]  M. Hernán,et al.  Prevalence of SARS-CoV-2 in Spain (ENE-COVID): a nationwide, population-based seroepidemiological study , 2020, The Lancet.

[28]  C. Reed,et al.  Seroprevalence of Antibodies to SARS-CoV-2 in Six Sites in the United States, March 23-May 3, 2020 , 2020, medRxiv.

[29]  N. Basta,et al.  Serodiagnostics for Severe Acute Respiratory Syndrome–Related Coronavirus-2 , 2020, Annals of Internal Medicine.

[30]  Christopher Earl,et al.  Preexisting and de novo humoral immunity to SARS-CoV-2 in humans , 2020, Science.

[31]  J. Wolchok,et al.  The many faces of the anti-COVID immune response , 2020, The Journal of experimental medicine.

[32]  A. Fauci,et al.  B‐cell responses to HIV infection , 2017, Immunological reviews.

[33]  Richard E. Joines.  South , 2014, Definitions.

[34]  K. Zuma,et al.  South African National HIV Prevalence, Incidence, Behaviour and Communication Survey, 2017: towards achieving the UNAIDS 90-90-90 targets , 2019 .

[35]  K. Sullivan,et al.  OpenEpi: Open Source Epidemiologic Statistics for Public Health. Version 2.3.1. , 2013 .